Anti-TCRa/b-Biotin, human, REA652, 100 t，130-113-537，美天旎

Clone REA652 recognizes the human α/β T cell receptor (TCR). The T cell receptor is a heterodimer composed of two transmembrane glycoprotein chains, α and β. In 95% of T cells the TCR consists of an α and β chain, whereas in 5% of T cells it has γ and δ chains. α and β chains are members of the Ig superfamily and consist of a constant and a polymorphic variable region. The variable region of the TCRα/β is involved in recognition of antigenic peptides presented by the MHC complex of antigen-presenting cells.

Additional information: Clone REA652 displays negligible binding to Fc receptors.

TCR a/b, IMD7, TCRA, TRAC, TRA, TRB

Technical specifications

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

• eliminate destabilizing amino acid motifs,
• increase specific bonding affinity for stronger, more accurate targeting, and
• optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).